Abstract:Bcl-B protein is an anti-apoptotic member of the Bcl-2 family protein that contains all the four BH (Bcl-2 homology) domains (BH1, BH2, BH3 and BH4) and a predicted C-terminal transmembrane domain. Our previous results showed that Bcl-B binds Bax and suppresses apoptosis induced by over-expression of Bax; however, Bcl-B does not bind or suppress Bak. To explore the molecular basis for the differential binding and suppression of Bax and Bak, we studied the BH3 dimerization domains of Bax and Bak. Chimeric mutants of Bax and Bak were generated that swapped the BH3 domains of these pro-apoptotic proteins. Bcl-B associated with and blocked apoptosis induced by mutant Bak containing the BH3 domain of Bax, but not mutant Bax containing the BH3 domain of Bak. In contrast, Bcl-XL protein bound and suppressed apoptosis induction by Bax, Bak and both BH3-domain chimeras. A strong correlation between binding and apoptosis suppression was also obtained using a series of alanine substitutions spanning the length of the Bax BH3 domain to identify critical residues for Bcl-B binding. Conversely, using structure-based modelling to design mutations in the BH3-binding pocket of Bcl-B, we produced two Bcl-B mutants (Leu86→Ala and Arg96→Gln) that failed to bind Bax and that also were unable to suppress apoptosis induced by Bax over-expression. In contrast, other Bcl-B mutants that still bound Bax retained protective activity against Bax-induced cell death, thus serving as a control. We conclude that, in contrast with some other anti-apoptotic Bcl-2-family proteins, a strong correlation exists for Bcl-B between binding to pro-apoptotic multidomain Bcl-2 family proteins and functional apoptosis suppression.

Evaluating the inhibitory priority of Bcl-xL to Bad, tBid and Bax by using live-cell imaging assay

Live-cell imaging analysis on the anti-apoptotic function of the Bcl-xL transmembrane carboxyl terminal domain

Characterization of the anti-apoptotic mechanism of Bcl-B

Computational analysis of binding free energies, hotspots and the binding mechanism of Bcl-xL/Bcl-2 binding to Bad/Bax

Influence of Apoptin on Up-Regulation of the Expression of Bad and Bax

Structure Assembly of Bcl-xL Through Α5–α5 and Α6–α6 Interhelix Interactions in Lipid Membranes

Full Anti-Apoptotic Function of Bcl-XL Complexed with Beclin-1 Verified by Live-Cell FRET Assays

Bim L Displacing Bcl-x L Promotes Bax Translocation During TNFα-induced Apoptosis

Stoichiometry and Regulation Network of Bcl-2 Family Complexes Quantified by Live-Cell FRET Assay

BimL directly neutralizes Bcl-xL to promote Bax activation during UV-induced apoptosis

Experimental Characterization of the Binding Affinities Between Proapoptotic BH3 Peptides and Antiapoptotic Bcl-2 Proteins

Differential Regulation of Bax and Bak by Anti-apoptotic Bcl-2 Family Proteins Bcl-B and Mcl-1

The progress of research on anti-apoptotic protein BFL1/hA1

A Conserved Hydrophobic Core At Bcl-X(L) Mediates Its Structural Stability And Binding Affinity With Bh3-Domain Peptide Of Pro-Apoptotic Protein

BimL involvement in Bax activation during UV irradiation-induced apoptosis.

Quantifying the Inhibitory Effect of Bcl‐xl on the Action of Mff Using Live‐cell Fluorescence Imaging

Bad is Essential for Bcl-xL-enhanced Bax Shuttling Between Mitochondria and Cytosol.

Real-time monitoring full length bid interacting with Bax during TNF-alpha-induced apoptosis.

Real-time monitoring full length bid interacting with Bax during TNF-α-induced apoptosis

Theoretical study on the selective binding of BH3-only protein BAD to antiapoptotic protein BCL-XL instead of MCL-1

[Expression, Purification and Activity Analyses of Three Bcl-2 Family Proteins].